A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

NCT05628103 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: SEP-363856

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.